The U.S. government will buy Siga Technologies Inc.’s $26-million worth of intravenous formulation of antiviral drug Tpoxx, the company said on Tuesday.
The company plans to deliver by next year the order for the IV treatment, which would be a vital option for patients unable to swallow the oral pill as monkeypox symptoms include rashes and blisters in the mouth.
